Dec 16, 2009
A Meta-Analysis: Tandem Vs Single Autologous Hematopoietic Cell Transplantation Myeloma - JNCI 2009
Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and...
17
Dec 12, 2009
NCT01023308: Phase 3 - Panobinostat or Placebo With Bortezomib & Dex in Relapsed Myeloma PANORAMA-1
PANORAMA Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome...
246
Dec 10, 2008
NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse
Myeloma X Relapse NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Multiple Myeloma RRMM - Myeloma X Relapse Time Frame:...
50
Dec 3, 2008
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With RRMM
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma A Study of...
52
Dec 14, 2007
NCT00424047: Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
Multiple Myeloma (010) MM-010 NCT00424047: A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated...
201
Dec 14, 2007
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
RRMM Relapsed and Refractory Multiple Myeloma NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma...
91
Dec 12, 2007
NCT00574288: Phase 1/2: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - GEN501 study
GEN501 study Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma Establishment of safety profile of HuMax-CD38 when given as...
430
Dec 8, 2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results total therapy 3
Br J Haematol 2007 Jul Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Bart...
163
Dec 9, 2004
NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Multiple Myeloma
ECOG-ACRIN Cancer Research Group ECOG E4A03 NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating...
278
Dec 4, 2004
PMID 6546971: Effective treatment of advanced multiple myeloma refractory to alkylating agents
N Engl J Med May 24, 1984 Effective treatment of advanced multiple myeloma refractory to alkylating agents. Barlogie B, Smith L,...
263
Dec 12, 2003
Single versus double autologous stem-cell transplantation for multiple myeloma
IFM - Time Frame: October 1994 and March 1997 IFM (Intergroupe Francophone du Myelome) N Engl J Med, 2003 Dec 25 Single versus double...
106
Dec 11, 2003
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
Multiple Myeloma (009) MM-009 NCT00056160 : Phase 3 - CC-5013 Plus Dex Versus Dex Alone in Previously Treated Subjects With Multiple...
148
Dec 13, 2002
NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM
Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT00048230 This...
130
Dec 16, 2000
Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999
Time Frame: December 1997 and June 1998 Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999 Antitumor...
106
Dec 13, 2000
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Time Frame: October 1996 and October 2000 Results of autologous stem cell transplant in multiple myeloma patients with renal failure...
57